STOCK TITAN

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON) will participate in the 44th Annual Cowen Health Care Conference, with the CEO joining a panel discussion on Novel Oncology Targets. The event will take place from March 4-6, 2024, in Boston, Massachusetts.
Positive
  • None.
Negative
  • None.

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th Annual Cowen Health Care Conference, taking place March 4-6, 2024, in Boston, Massachusetts.

Kronos Bio President and Chief Executive Officer Norbert Bischofberger, Ph.D., will participate in the “Novel Oncology Targets” panel discussion on Tuesday, March 5, at 9:10 a.m. ET.

A live audio webcast of the event will be available on the Investors and Media section of the Kronos Bio website at www.kronosbio.com. A replay of the webcast will be available for 30 days following the event.

About Kronos Bio, Inc.
Kronos Bio is a biopharmaceutical company that is advancing an investigational CDK9 inhibitor compound, KB-0742, in clinical trials as a treatment for MYC-amplified solid tumors and other transcriptionally addicted solid tumors as well as a preclinical development candidate, KB-9558, targeting the KAT domain of p300 for multiple myeloma. The Company’s scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com/ or follow the Company on LinkedIn.

Media Contact:
Sarah Connors
Vice President of Corporate Affairs, Kronos Bio
857-290-7305
sconnors@kronosbio.com

Investor Contact:
Margaux Bennett
Vice President, Business Development and Investor Relations, Kronos Bio
650-781-5026
mbennett@kronosbio.com


FAQ

When will Kronos Bio participate in the 44th Annual Cowen Health Care Conference?

Kronos Bio will participate in the conference from March 4-6, 2024.

What is the CEO's name of Kronos Bio, Inc.?

The CEO of Kronos Bio, Inc. is Norbert Bischofberger, Ph.D.

What is the topic of the panel discussion that Kronos Bio will participate in?

Kronos Bio will participate in the 'Novel Oncology Targets' panel discussion.

Where will the 44th Annual Cowen Health Care Conference take place?

The conference will take place in Boston, Massachusetts.

Where can investors access the live audio webcast of the event?

Investors can access the live audio webcast on the Investors and Media section of the Kronos Bio website at www.kronosbio.com.

Kronos Bio, Inc.

NASDAQ:KRON

KRON Rankings

KRON Latest News

KRON Stock Data

63.10M
43.75M
19.59%
44.68%
1.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN MATEO

About KRON

kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.